文献速递头颈技术与安全PETMR

原发性甲状旁腺功能亢进且常规影像不确定患者的18F氟胆碱PET/MR成像:一项前瞻性先导研究

18F Fluorocholine PET/MR Imaging in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging: A Prospective Pilot Study.
PubMed 文献 · Radiology · 2017-01-25

前瞻性纳入10例生化诊断原发性甲状旁腺功能亢进、超声和99mTc甲氧异腈闪烁显像阴性或不确定的患者,行18F氟胆碱PET/MR成像,以术中定位和组织学为参考标准。PET/MR正确检出10个腺瘤中的9个(敏感度90%,阳性预测值100%);腺瘤SUVmax中位数4.9显著高于甲状腺2.7(P=0.008)。作者指出需更多病例验证,四腺体增生定位准确性尚待研究。

要点

  • 10例常规影像不确定的患者中,18F氟胆碱PET/MR检出9/10腺瘤,敏感度90%,阳性预测值100%。
  • 腺瘤SUVmax中位数4.9高于甲状腺2.7(P=0.008),可辅助区分甲状旁腺与甲状腺摄取。
  • 1例四腺体增生中3个增生腺体未被PET/MR定位。

核心结论

  • 常规影像结果不确定时,18F氟胆碱PET/MR可高准确度定位腺瘤并提供详细解剖信息。
  • 作者指出需更多病例验证初步结果,四腺体增生患者的腺体定位准确性尚待研究。

研究设计与样本

  • 前瞻性先导研究,2015年5月至12月纳入10例生化诊断原发性甲状旁腺功能亢进且超声和99mTc甲氧异腈闪烁显像结果不确定的患者,平均年龄70.4岁(范围58-82岁)。
  • 所有患者签署知情同意,经机构审查委员会批准;注射3 MBq/kg 18F氟胆碱后行PET成像,随后行钆增强前后T1和T2加权MR成像。
  • 以术中定位和组织学结果为参考标准计算敏感度和阳性预测值;用Wilcoxon秩检验比较异常甲状旁腺与生理性甲状腺摄取SUVmax的均值差异,并采用Wilcoxon秩和检验。

关键影像表现/征象

  • 单独MR成像显示5例真阳性病灶和1例假阳性病灶。
  • 18F氟胆碱PET/MR正确检出10个腺瘤中的9个,无异假阳性。
  • 1例四腺体增生患者中3个增生腺体未被定位。

诊断标准与关键数值

  • 18F氟胆碱PET/MR定位腺瘤的敏感度为90%(9/10),阳性预测值为100%。
  • 9个术前检出腺瘤的SUVmax中位数为4.9(四分位距2.45-7.35),甲状腺SUV为2.7(四分位距1.6-3.8),差异有统计学意义(P=0.008)。

临床应用与阅片要点

  • 对超声和99mTc甲氧异腈闪烁显像阴性或不确定的原发性甲状旁腺功能亢进患者,可参考本研究的18F氟胆碱PET/MR定位结果。
  • 阅片时需注意四腺体增生患者中增生腺体可能未被PET/MR定位(本研究1例中3个增生腺体未定位)。

局限性

  • 作者指出需更多病例验证初步结果。
  • 四腺体增生患者腺体定位的准确性尚待研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To investigate the performance of flourine 18 (18F) fluorocholine (FCH) positron emission tomography (PET)/magnetic resonance (MR) imaging in patients with hyperparathyroidism and nonlocalized disease who have negative or inconclusive results at ultrasonography (US) and technetium 99m (99mTc) sestamibi scintigraphy. Materials and Methods This study was approved by the institutional review board. Between May and December 2015, 10 patients (mean age, 70.4 years; range, 58-82 years) with biochemical primary hyperparathyroidism and inconclusive results at US and 99mTc sestamibi scintigraphy were prospectively enrolled. All patients gave informed consent. Directly after administration of 3 MBq/kg of FCH, PET imaging was performed, followed by T1- and T2-weighted MR imaging before and after gadolinium enhancement. Intraoperative localization and histologic results were the reference standard for calculating sensitivity and positive predictive value. The Wilcoxon rank test was used to calculate the mean difference in maximum standardized uptake value (SUVmax) between abnormal parathyroid uptake and physiologic thyroid uptake. The Wilcoxon rank-sum test was performed. Results MR imaging alone showed true-positive lesions in five patients and a false-positive lesion in one patient. FCH PET/MR imaging allowed correct localization of nine of 10 adenomas (90% sensitivity), without any false-positive results (100% positive predictive value). One patient had four-gland hyperplasia, of which three hyperplastic glands were not localized. The median SUVmax of the nine preoperatively identified adenomas was 4.9 (interquartile range, 2.45-7.35), which was significantly higher than the SUV, 2.7 (interquartile range, 1.6-3.8), of the thyroid (P = .008). Conclusion FCH PET/MR imaging allowed localization of adenomas with high accuracy when conventional imaging results were inconclusive and provided detailed anatomic information. More patients must be examined to confirm our initial results, and the accuracy of FCH PET/MR imaging for localization of glands in patients with four-gland hyperplasia remains to be investigated. © RSNA, 2017.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Kluijfhout WP, Pasternak JD, Gosnell JE, et al. 18F Fluorocholine PET/MR Imaging in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging: A Prospective Pilot Study. Radiology. 2017. PMID: 28121522. doi:10.1148/radiol.2016160768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。